Company intelligence / Profile preview

Barbara Ensoli

Rome, Italy

Ownership: Private
Development stage: Other

Overview

Vaxent is a clinical-stage biotechnology company focused on the development of a therapeutic vaccine for HIV/AIDS based on the research of Dr. Barbara Ensoli. The company's lead candidate is a vaccine targeting the HIV-1 Tat protein, which plays a crucial role in viral replication and immune evasion. Unlike traditional vaccines that target structural proteins, Vaxent's approach aims to restore immune system function and reduce the viral reservoir in patients already receiving antiretroviral therapy (cART). The company is a spin-off from the National AIDS Center at the Istituto Superiore di Sanità (ISS) in Italy.

Therapeutic areas: Infectious Diseases
Modalities: VaccineProtein
Industry: Biotech

Partnerships

Istituto Superiore di Sanità (ISS)

Beyond the preview

Go deeper on Barbara Ensoli.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Barbara Ensoli.

Explore the full profile